Trastuzumab biosimilar - Prestige Biopharma

Drug Profile

Trastuzumab biosimilar - Prestige Biopharma

Alternative Names: HD 201; Hervelous

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanwha Biologics
  • Developer Prestige BioPharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer; Gastric cancer

Most Recent Events

  • 28 Jun 2018 Prestige Biopharma and Alvogen enter into a license and supply agreement in Breast cancer and Gastric cancer in Central and Eastern Europe
  • 28 Jun 2018 Prestige Biopharma expects regulatory filing of trastuzumab biosimilar with the European Medicines Agency and the US FDA in 2019
  • 01 Dec 2017 Phase-III clinical trials in Breast cancer (Combination therapy, Late-stage disease) in Malaysia (IV) (NCT03013504)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top